+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage



Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage



JAMA 292(8): 952-960



The majority of Medicare drug benefits in managed care (Medicare + Choice) have annual dollar limits or caps and many beneficiaries face temporary but potentially significant gaps in coverage after exceeding caps before the end of the year. In the new national Medicare drug benefit, beneficiaries with high medication expenditures will also face a period without drug coverage when their total drug costs exceed annual caps but are not high enough to qualify for catastrophic coverage. To describe strategies adopted by beneficiaries exceeding annual drug benefit caps to lower prescription costs, the type of medications involved, and their financial burden. A survey (completed in 2002) of Medicare + Choice beneficiaries aged 65 years and older with high medication costs and benefits capped on the plan's share of drug costs (65% response rate). The different caps offered in different counties were used as a natural experiment. Study participants (n = 665) exceeded a 750 dollars or 1200 dollars yearly cap in 2001 and had coverage gaps of 75 to 180 days. Control participants (n = 643) had 2000 dollars caps, which they did not exceed. Study and control participants were matched by average total drug expenditures per month. Proportion of beneficiaries reporting specific strategies to decrease medication costs, medications affected, and difficulty paying for prescriptions. In multivariate analyses adjusting for demographic and health characteristics, a higher proportion of patients exceeding caps reported using less prescribed medication than controls (18% vs 10%, respectively; P<.001), but similar proportions reported stopping medications completely (8% for both, P =.86) and of not starting prescribed medications (6% vs 5%, P =.39). Patients exceeding caps more often called pharmacies to find the best price (46% vs 29%, P<.001), switched medications (15% vs 9%, P =.002), used samples (34% vs 27%, P =.006), and had difficulty paying for prescriptions (62% vs 37%, P<.001). Twelve of the 20 therapeutic classes most often affected by decreases in use of medication were for chronic health problems such as hypertension, hyperlipidemia, and emphysema or asthma. Medicare beneficiaries often decreased use of essential medications and experienced difficulty paying for prescriptions during gaps in coverage. Health professionals need to explore how they can lessen the impact of caps on patients' health and financial burden.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 048675800

Download citation: RISBibTeXText

PMID: 15328327

DOI: 10.1001/jama.292.8.952


Related references

Medicare drug beneficiaries and cost-lowering strategies. JAMA 293(5): 552-3; Author Reply 553, 2005

Effect of cost sharing on prescription drug use by Medicare beneficiaries prior to the Medicare Drug Benefit and potential adverse selection in the benefit. Journal of the American Pharmacists Association 49(1): 18-25, 2009

Cost-related medication nonadherence among elderly and disabled medicare beneficiaries: a national survey 1 year before the medicare drug benefit. Archives of Internal Medicine 166(17): 1829-1835, 2006

Effect of prescription drug coverage on the cost of care to Medicare beneficiaries with asthma. Expert Review of Pharmacoeconomics and Outcomes Research 4(4): 421-428, 2004

Medication strategies used by Medicare beneficiaries who reach the Part D standard drug-benefit threshold. American Journal of Health-System Pharmacy 65(11): 1062-1070, 2008

A Medicare prescription drug benefit: focusing on coverage and cost. Issue Brief 2002(538): 1-6, 2002

Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation 117(10): 1261-1268, 2008

Prescription drug coverage and effects on drug expenditures among elderly Medicare beneficiaries. Health Services Research 43(3): 810-832, 2008

Drug use patterns in severely mentally ill Medicare beneficiaries: impact of discontinuities in drug coverage. Health Services Research 43(2): 496-514, 2008

Drug coverage and drug purchases by Medicare beneficiaries with hypertension. Health Affairs 19(2): 219-230, 2000

Falling into the coverage gap: Part D drug costs and adherence for Medicare Advantage prescription drug plan beneficiaries with diabetes. Health Services Research 45(2): 355-375, 2010

Congress glumly moves towards Medicare drug benefit: but the cost is expected to be very high, and coverage limited. Lancet 361(9376): 2216-2216, 2003

Medicare beneficiaries and drug coverage. Health Affairs 19(2): 248-256, 2000

Medicare drug coverage 101: everything you need to know about the new Medicare prescription drug benefit. Care Management Journals 7(1): 11-33, 2007

Closing the Medicare Doughnut Hole: Changes in Prescription Drug Utilization and Out-of-Pocket Spending Among Medicare Beneficiaries With Part D Coverage After the Affordable Care Act. Medical Care 55(1): 43-49, 2016